Search Results - Therapeutics

22 Results

Sort By:

Biosynthetic Gene Cluster for the Peptide Antibiotic Enduracidin

Technology Description To produce a library of S. fungicidicus mutants, an in vitro transposon-based method was devised to randomly insert a selectable marker and oriT element in fosmid inserts carrying segments of the enramycin biosynthetic gene cluster and adjacent regions. This library of mutagenized fosmids was screened to identify specific disrupted...

Published: 3/13/2024 | Inventor(s): T. Zabriskie, Xihou 希厚 Yin 银

Keywords(s): Biomedical, Biotechnology, Medical Science & Technologies, pharmaceuticals

Category(s): Therapeutics

mRNA Therapeutic Against the SARS-CoV-2 Spike Protein

Background Vaccines have shown great efficacy against SARS-CoV-2, the pathogen of COVID-19; however, methods of treatment are required for patients suffering from COVID‑19. More than 15 million cases with over 600,000 deaths have resulted from the ongoing coronavirus disease 2019 (COVID-19). SARS-CoV-2, the pathogen of COVID-19, is a β-coronavirus...

Published: 8/4/2022 | Inventor(s): Gaurav Sahay, Anindit Mukherjee, Jeonghwan Kim

Keywords(s): antiviral, Drug, Drug Delivery, mRNA, mRNA carrier, mRNA delivery

Category(s): Therapeutics

Treatment for Metabolic Syndrome and Obesity Related Diseases

Background Abdominal obesity is the most commonly observed component of metabolic syndrome and a major risk factor for type II diabetes and cardiovascular disease. In addition to obesity, an individual’s risk of cardiovascular disease and type II diabetes is strongly correlated to a series of risk factors, collectively referred to as metabolic...

Published: 8/4/2022 | Inventor(s): Jan Frederik Stevens, Paul Blakemore, Ines Paraiso, Luce Mattio

Keywords(s): Chemical Synthesis, medicinal, Metabolic syndrome, Obesity, pharmaceuticals, Type 2 Diabetes

Category(s): Therapeutics

Morpholino Oligomers to Prevent and Treat Coronavirus Infection

This technology licensing opportunity relates to antisense agents for treating or preventing a SARS-CoV-2 infection. The antisense agents are peptide-conjugated morpholino oligomers targeting pre-mRNA of a host (human) gene that encodes a protease. Some antisense agents included within the scope of this technology include agents previously shown to...

Published: 5/26/2021 | Inventor(s): Hong Moulton, David Stein, Eva Bottcher-Friebershauser

Keywords(s):

Category(s): Therapeutics

Antisense Agents for Treating SARS-CoV-2 Infection

Background In December 2019, cases of an acute respiratory disease were reported from Wuhan, the capital of Hubei province in China. The number of infections increased rapidly and spread to other areas of China and on January 13th, 2020, the first case was reported outside of China. The causative agent was identified as a novel coronavirus (CoV)...

Published: 7/31/2023 | Inventor(s): David Stein, Hong Moulton, Kyle Rosenke, Heinrich Feldmann

Keywords(s): antisense, coronavirus, covid-19, Drug, SARS-CoV-2, Therapeutic

Category(s): Therapeutics

New Drugs for Treatment of Type 1 Diabetes

Technology Description Oregon State University is seeking a licensee to develop and commercialize a new family of compounds that target the Ah receptor for treatment of Type 1 Diabetes. The compounds are based on the parental compound 11-Cl-BBQ, the use of which is described PCT patent application No. US2015/057873, in U.S. patent No. 10,308,649, and...

Published: 8/3/2023 | Inventor(s): Siva Kolluri, Nancy Kerkvliet, Jit Chakravarty, Sebastian Bernales

Keywords(s): Diabetes, pharmaceuticals, Therapeutic, Type 1 Diabetes

Category(s): Therapeutics

Substituted Phenols and Benzenes for Pharmaceuticals, Agrochemicals and Synthetic Materials

Technology Description This technology licensing opportunity is for novel phenol and benzene compounds with any number of substituents and complete positional selectivity. Synthesis of the compounds is achieved by a new synthetic method. The method provides a one-step conversion of readily available starting materials to give phenols with complete...

Published: 5/23/2023 | Inventor(s): Chris Beaudry, Xiaojie Zhang

Keywords(s): agrochemical, benzenes, chemistry, medicinal, organic, pharmaceuticals, phenols, polymer, substituted, synthesis

Category(s): Agricultural, Chemical, Therapeutics

Treatment for Hypertension

Technology Description This technology opportunity provides antisense oligomer compounds and methods for the treatment of hypertension that overcome the various limitations and drawbacks associated with the use of substrate inhibitors. The compounds accumulate in the kidney, which allows for efficient dosing, and can be developed for transdermal, subcutaneous,...

Published: 1/16/2023 | Inventor(s): Patrick Iversen, Andrew Annalora

Keywords(s): Hypertension, pharmaceuticals, Transplantation

Category(s): Therapeutics

Synthetic Cephalotaxine Synthesis and New Anti-Cancer Compounds

Technology Description Oregon State University is seeking a licensee for an improved method to synthesize chemotherapeutic Homoharringtonine (HHT) that overcomes the need to use plant derived cephalotaxine. The synthetic method provides a high yield of chemically synthesized cephalotaxine as an HHT precursor and also enables the synthesis of novel...

Published: 1/13/2023 | Inventor(s): Chris Beaudry, Xuan Ju

Keywords(s):

Category(s): Biological Materials, Chemical, Therapeutics

Photoreactor for Treatment of Jaundice

Technology Description Oregon State University is seeking a licensee or research collaborator for development or commercialization of a microfluidic visible light photoreactor for the treatment of jaundice in neonatal patients. The device enables safe extracorporeal blood treatment, making it an excellent replacement for equally effective, yet risky,...

Published: 1/16/2023 | Inventor(s): John Lahmann, Adam Higgins

Keywords(s): Advanced Technology and Manufacturing Inst. (ATAMI), Bilirubin, Blood, hyperbilirubinemia, light, Medical Science & Technologies, Neonatal, Newborn, Photoreactor, Sepsis, treatment

Category(s): Medical Devices, Therapeutics, Engineering

1 2 3